JPWO2019246110A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019246110A5 JPWO2019246110A5 JP2021520087A JP2021520087A JPWO2019246110A5 JP WO2019246110 A5 JPWO2019246110 A5 JP WO2019246110A5 JP 2021520087 A JP2021520087 A JP 2021520087A JP 2021520087 A JP2021520087 A JP 2021520087A JP WO2019246110 A5 JPWO2019246110 A5 JP WO2019246110A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 64
- 102000004965 antibodies Human genes 0.000 claims description 54
- 108090001123 antibodies Proteins 0.000 claims description 54
- 239000000427 antigen Substances 0.000 claims description 39
- 102000038129 antigens Human genes 0.000 claims description 39
- 108091007172 antigens Proteins 0.000 claims description 39
- 206010014733 Endometrial cancer Diseases 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 9
- 206010061424 Anal cancer Diseases 0.000 claims description 6
- 201000011165 anus cancer Diseases 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 102000010567 DNA Polymerase II Human genes 0.000 claims description 4
- 108010063113 DNA Polymerase II Proteins 0.000 claims description 4
- 101700008821 EXO Proteins 0.000 claims description 4
- 101700083023 EXRN Proteins 0.000 claims description 4
- 230000035693 Fab Effects 0.000 claims description 4
- 208000002030 Merkel Cell Carcinoma Diseases 0.000 claims description 4
- 229920002393 Microsatellite Polymers 0.000 claims description 4
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 4
- 230000033607 mismatch repair Effects 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 2
- 206010025310 Other lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010038038 Rectal cancer Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000009030 carcinoma Diseases 0.000 claims description 2
- 201000011231 colorectal cancer Diseases 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000009251 multiple myeloma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862687673P | 2018-06-20 | 2018-06-20 | |
| US62/687,673 | 2018-06-20 | ||
| US201862756319P | 2018-11-06 | 2018-11-06 | |
| US62/756,319 | 2018-11-06 | ||
| PCT/US2019/037750 WO2019246110A1 (en) | 2018-06-20 | 2019-06-18 | Anti-pd-1 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527714A JP2021527714A (ja) | 2021-10-14 |
| JPWO2019246110A5 true JPWO2019246110A5 (ko) | 2022-06-20 |
Family
ID=67138174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520087A Pending JP2021527714A (ja) | 2018-06-20 | 2019-06-18 | 抗ｐｄ−１抗体及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200095322A1 (ko) |
| EP (2) | EP4349411A3 (ko) |
| JP (1) | JP2021527714A (ko) |
| KR (1) | KR20210030366A (ko) |
| CN (1) | CN112955464A (ko) |
| AU (1) | AU2019288276A1 (ko) |
| CA (1) | CA3104467A1 (ko) |
| IL (1) | IL279455A (ko) |
| MA (1) | MA52949A (ko) |
| MX (1) | MX2020014158A (ko) |
| PH (1) | PH12020552221A1 (ko) |
| SG (1) | SG11202012671QA (ko) |
| TW (1) | TWI835808B (ko) |
| WO (1) | WO2019246110A1 (ko) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190292188A1 (en) | 2018-02-27 | 2019-09-26 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CA3105721A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| MX2021009682A (es) | 2019-02-15 | 2021-11-12 | Incyte Corp | Biomarcadores de cinasa 2 dependientes de ciclinas y sus usos. |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| KR20220064369A (ko) | 2019-08-14 | 2022-05-18 | 인사이트 코포레이션 | Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물 |
| WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| CA3166549A1 (en) * | 2020-01-03 | 2021-07-08 | Incyte Corporation | Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2024097328A1 (en) | 2022-11-03 | 2024-05-10 | Incyte Corporation | Combination therapies comprising an anti-gitr antibody for treating cancers |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US192A (en) | 1837-05-15 | Machine for cutting | ||
| US6803A (en) | 1849-10-16 | Double-cylinder spike-machine | ||
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質／（ポリ）ペプチドライブラリー |
| BR0013542A (pt) | 1999-08-23 | 2002-05-14 | Dana Farber Cancer Inst Inc | Moléculas b7-4 e usos para as mesmas |
| JP4896327B2 (ja) | 1999-08-23 | 2012-03-14 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｐｄ−１、ｂ７−４の受容体、およびその使用 |
| CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| AU2002258941A1 (en) | 2001-04-20 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| AU2004253868B2 (en) | 2003-06-13 | 2011-06-16 | Biogen Ma Inc. | Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| US8087074B2 (en) | 2004-10-15 | 2011-12-27 | Symantec Corporation | One time password |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| US8062852B2 (en) | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
| TR201901507T4 (tr) * | 2014-02-04 | 2019-02-21 | Merck Sharp & Dohme | Kanseri tedavi etmeye yönelik bir pd-1 antagonsitinin ve bir vegfr inhibitörünün kombinasyonu. |
| TWI693232B (zh) * | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| US20160158360A1 (en) * | 2014-12-05 | 2016-06-09 | Genentech, Inc. | Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists |
| TW201709929A (zh) * | 2015-06-12 | 2017-03-16 | 宏觀基因股份有限公司 | 治療癌症的聯合療法 |
| EP3328418A1 (en) * | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| GEP20227419B (en) | 2015-07-30 | 2022-10-10 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
-
2019
- 2019-06-18 WO PCT/US2019/037750 patent/WO2019246110A1/en unknown
- 2019-06-18 US US16/444,691 patent/US20200095322A1/en active Pending
- 2019-06-18 MA MA052949A patent/MA52949A/fr unknown
- 2019-06-18 SG SG11202012671QA patent/SG11202012671QA/en unknown
- 2019-06-18 KR KR1020217001750A patent/KR20210030366A/ko unknown
- 2019-06-18 CA CA3104467A patent/CA3104467A1/en active Pending
- 2019-06-18 MX MX2020014158A patent/MX2020014158A/es unknown
- 2019-06-18 EP EP24151431.4A patent/EP4349411A3/en active Pending
- 2019-06-18 EP EP19735113.3A patent/EP3810651A1/en active Pending
- 2019-06-18 JP JP2021520087A patent/JP2021527714A/ja active Pending
- 2019-06-18 TW TW108121123A patent/TWI835808B/zh active
- 2019-06-18 AU AU2019288276A patent/AU2019288276A1/en active Pending
- 2019-06-18 CN CN201980051661.8A patent/CN112955464A/zh active Pending
-
2020
- 2020-12-15 IL IL279455A patent/IL279455A/en unknown
- 2020-12-18 PH PH12020552221A patent/PH12020552221A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019246110A5 (ko) | ||
| HRP20201928T1 (hr) | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1 | |
| JP2022101693A5 (ko) | ||
| HRP20211058T1 (hr) | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 | |
| JP2017048240A5 (ko) | ||
| JP2020527355A5 (ko) | ||
| JP2023002562A5 (ko) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| IL276695A (en) | Antibodies, pharmaceuticals and their uses | |
| JP2018508188A5 (ko) | ||
| JP2020502271A5 (ko) | ||
| JP2012532851A5 (ko) | ||
| RU2012103212A (ru) | Tlr3 связывающие агенты | |
| RU2010132956A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
| JP2023037000A5 (ko) | ||
| JP2023089245A5 (ko) | ||
| IL276675B1 (en) | Anti-pd-1 antibodies and uses thereof | |
| JPWO2020020281A5 (ko) | ||
| JP2020522280A5 (ko) | ||
| JPWO2022114163A5 (ko) | ||
| JPWO2021138467A5 (ko) | ||
| JP2022122865A5 (ko) | ||
| JPWO2019228514A5 (ko) | ||
| JPWO2020144178A5 (ko) | ||
| JPWO2020081928A5 (ko) |